Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,460.00    44.00 (3.11%)
Bid:
1,453.00
Ask:
1,454.00
Spread: 1.00 (0.069%)
Market Cap: £3.10b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Blocklisting Interim Review

6 Oct 2014 15:58

RNS Number : 5739T
Hikma Pharmaceuticals Plc
06 October 2014
 



 

Block Listing Six Monthly Return

 

Information provided on this form must be typed or printed electronically and provided to an RIS.

 

Date: 6 October 2014

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

&

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

&

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("MIP")

Period of return

From:

1 April 2014

To:

30 September 2014

Balance of unallotted securities under scheme(s) from previous return:

SOP: 967,900 ordinary shares of 10 pence

LTIP: 400,050 ordinary shares of 10 pence

MIP: 378,360 ordinary shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 0 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 38,200 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 356,752 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 929,700 ordinary shares of 10 pence

LTIP: 400,050 ordinary shares of 10 pence

MIP: 21,608 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

 

 

 

 

Stock Option Plan ("SOP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2014

-

-

967,900

Blocklisting return 01/04/2014

10/04/2014

0

8,500

959,400

25/04/2014

0

2,500

956,900

23/05/2014

0

1,000

955,900

12/06/2014

0

2,500

953,400

12/06/2014

0

1,700

951,700

21/08/2014

0

6,000

945,700

21/08/2014

0

7,500

938,200

12/09/2014

0

8,500

929,700

Blocklisting return 30/09/2014

 

Long Term Incentive Plan ("LTIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2014

-

-

400,050

Blocklisting return 01/04/2014

30/09/2014

-

-

400,050

Blocklisting return 01/10/2014

 

 

Management Incentive Plan ("MIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2014

-

-

378,360

Blocklisting return 01/04/14

18/05/2014

0

261,480

116,880

12/06/2014

0

11,619

105,261

13/06/2014

0

77,487

27,774

30/06/2014

0

741

27,033

07/08/2014

0

2,856

24,177

22/08/2014

0

794

23,383

04/09/2014

0

300

23,083

12/09/2014

0

1,475

21,608

 Blocklisting return 01/10/14

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRKMMGGDVVGDZM
Date   Source Headline
15th Apr 201912:23 pmRNSAnnual Financial Report
1st Apr 20195:42 pmRNSTotal Voting Rights
1st Apr 20195:11 pmRNSBlock listing Interim Review
18th Mar 20193:09 pmRNSDirector/PDMR Shareholding
15th Mar 201910:32 amRNSDirector/PDMR Shareholding
14th Mar 20199:14 amRNSDirector/PDMR Shareholding
13th Mar 20191:50 pmRNSDirector/PDMR Shareholding
13th Mar 20191:49 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSFinal Results
12th Mar 20197:00 amRNSDirectorate Change
1st Mar 20194:51 pmRNSTotal Voting Rights
28th Feb 20199:00 amRNSHikma establishes partnership with Melinta in MENA
27th Feb 20191:26 pmRNSBlock listing Interim Review
26th Feb 201911:08 amRNSNotice of Results
11th Feb 201910:11 amRNSDirector/PDMR Shareholding
1st Feb 20193:43 pmRNSTotal Voting Rights
29th Jan 20199:00 amRNSHikma launches Mitomycin for Injection
3rd Jan 20199:00 amRNSHikma announces agreement with Sciecure Pharma
19th Dec 20186:30 pmRNSShire
10th Dec 20189:00 amRNSHikma launches Clobazam
3rd Dec 201810:30 amRNSTotal Voting Rights
27th Nov 20189:00 amRNSHikma announces injectable licensing agreement
19th Nov 20189:00 amRNSHikma launches Triazolam Tablets
13th Nov 201811:15 amRNSHolding(s) in Company
8th Nov 20189:44 amRNSHikma announces agreement with Vectura
8th Nov 20187:00 amRNSHikma announces agreement with Vectura
8th Nov 20187:00 amRNSTrading Statement
1st Nov 201812:39 pmRNSTotal Voting Rights
16th Oct 20184:30 pmRNSBlock listing Interim Review
1st Oct 201810:53 amRNSTotal Voting Rights
1st Oct 201810:23 amRNSHolding(s) in Company
3rd Sep 201811:05 amRNSTotal Voting Rights
30th Aug 20189:58 amRNSHolding(s) in Company
28th Aug 201812:45 pmRNSHolding(s) in Company
22nd Aug 20189:41 amRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSHalf-year Report
23rd Jul 20189:00 amRNSNotice of Results
9th Jul 20189:00 amRNSHikma enters licensing partnership with Perrigo
2nd Jul 20184:56 pmRNSTotal Voting Rights
15th Jun 20183:24 pmRNSDirector/PDMR Shareholding
8th Jun 201811:50 amRNSDirector/PDMR Shareholding
4th Jun 201810:29 amRNSDirector/PDMR Shareholding
4th Jun 20189:00 amRNSHikma appoints Chief Transformation Officer
1st Jun 201811:34 amRNSTotal Voting Rights
30th May 20183:20 pmRNSDirector/PDMR Shareholding
30th May 20189:00 amRNSHikma launches Methylergonovine Maleate Tablets
23rd May 201810:20 amRNSDirector/PDMR Shareholding
18th May 20181:01 pmRNSAGM Results
18th May 20187:00 amRNSTrading Statement
17th May 20181:45 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.